28067693|t|Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial
28067693|a|Perioperative handling of surgical patients with opioid dependency represents an important clinical problem. Animal studies suggest that ketamine attenuates central sensitization and hyperalgesia and thereby reduces postoperative opioid tolerance. We hypothesized that intraoperative ketamine would reduce immediate postoperative opioid consumption compared with placebo in chronic pain patients with opioid dependency undergoing lumbar spinal fusion surgery. Primary outcome was morphine consumption 0 to 24 hours postoperatively. Secondary outcomes were acute pain at rest and during mobilization 2 to 24 hours postoperatively (visual analogue scale), adverse events, and persistent pain 6 months postoperatively. One hundred fifty patients were randomly assigned to intraoperative S-ketamine bolus 0.5 mg/kg and infusion 0.25 mg·kg·h or placebo. Postoperatively, patients received their usual opioids, paracetamol and IV patient-controlled analgesia with morphine. In the final analyses, 147 patients were included. Patient-controlled analgesia IV morphine consumption 0 to 24 hours postoperatively was significantly reduced in the ketamine group compared with the placebo group: 79 (47) vs 121 (53) mg IV, mean difference 42 mg (95% confidence interval -59 to -25), P < 0.001. Sedation was significantly reduced in the ketamine group 6 and 24 hours postoperatively. There were no significant differences regarding acute pain, nausea, vomiting, hallucinations, or nightmares. Back pain at 6 months postoperatively compared with preoperative pain was significantly more improved in the ketamine group compared with the placebo group, P = 0.005. In conclusion, intraoperative ketamine significantly reduced morphine consumption 0 to 24 hours after lumbar fusion surgery in opioid - dependent patients. The trend regarding less persistent pain 6 months postoperatively needs further investigation.
28067693	0	14	Intraoperative	T079	C0456904
28067693	15	23	ketamine	T109,T121	C0022614
28067693	24	31	reduces	T080	C0392756
28067693	32	41	immediate	T079	C0205253
28067693	42	55	postoperative	T079	C0032790
28067693	56	62	opioid	T109,T121	C0002772
28067693	63	74	consumption	T169	C1512806
28067693	81	102	spinal fusion surgery	T061	C0919636
28067693	106	118	chronic pain	T184	C0150055
28067693	119	127	patients	T101	C0030705
28067693	133	139	opioid	T109,T121	C0002772
28067693	140	150	dependency	T080	C0851827
28067693	154	164	randomized	T062	C0034656
28067693	166	179	blinded trial	T062	C2347038
28067693	180	193	Perioperative	T079	C1518988
28067693	194	202	handling	T033	C1832073
28067693	206	223	surgical patients	T101	C0871463
28067693	229	235	opioid	T109,T121	C0002772
28067693	236	246	dependency	T080	C0851827
28067693	261	270	important	T080	C3898777
28067693	271	279	clinical	T080	C0205210
28067693	280	287	problem	T033	C0033213
28067693	289	303	Animal studies	T008	C0683949
28067693	317	325	ketamine	T109,T121	C0022614
28067693	326	336	attenuates	T052	C0599946
28067693	337	358	central sensitization	T047	C2938905
28067693	363	375	hyperalgesia	T184	C0020429
28067693	388	395	reduces	T080	C0392756
28067693	396	409	postoperative	T079	C0032790
28067693	410	416	opioid	T109,T121	C0002772
28067693	410	426	opioid tolerance	UnknownType	C0240601
28067693	431	443	hypothesized	T078	C1512571
28067693	449	463	intraoperative	T079	C0456904
28067693	464	472	ketamine	T109,T121	C0022614
28067693	479	485	reduce	T080	C0392756
28067693	486	495	immediate	T079	C0205253
28067693	496	509	postoperative	T079	C0032790
28067693	510	516	opioid	T109,T121	C0002772
28067693	517	528	consumption	T169	C1512806
28067693	543	550	placebo	T122	C1696465
28067693	554	566	chronic pain	T184	C0150055
28067693	567	575	patients	T101	C0030705
28067693	581	587	opioid	T109,T121	C0002772
28067693	588	598	dependency	T080	C0851827
28067693	610	638	lumbar spinal fusion surgery	T061	C0186045
28067693	640	655	Primary outcome	T080	C3274433
28067693	660	668	morphine	T109,T121	C0026549
28067693	669	680	consumption	T169	C1512806
28067693	681	694	0 to 24 hours	T079	C0439585
28067693	695	710	postoperatively	T079	C0032790
28067693	712	730	Secondary outcomes	T080	C3274440
28067693	736	754	acute pain at rest	T184	C0234253
28067693	766	778	mobilization	T061	C0185112
28067693	779	792	2 to 24 hours	T079	C0439585
28067693	793	808	postoperatively	T079	C0032790
28067693	810	831	visual analogue scale	T060	C3536884
28067693	834	848	adverse events	T046	C0877248
28067693	854	864	persistent	T079	C0205322
28067693	865	869	pain	T184	C0030193
28067693	879	894	postoperatively	T079	C0032790
28067693	914	922	patients	T101	C0030705
28067693	928	945	randomly assigned	T062	C0034656
28067693	949	963	intraoperative	T079	C0456904
28067693	964	974	S-ketamine	T109,T121	C2825616
28067693	975	1003	bolus 0.5 mg/kg and infusion	T061	C1511237
28067693	1020	1027	placebo	T122	C1696465
28067693	1029	1044	Postoperatively	T079	C0032790
28067693	1046	1054	patients	T101	C0030705
28067693	1076	1083	opioids	T109,T121	C0002772
28067693	1085	1096	paracetamol	T109,T121	C0000970
28067693	1104	1132	patient-controlled analgesia	T061	C0078944
28067693	1138	1146	morphine	T109,T121	C0026549
28067693	1155	1169	final analyses	T170	C3899115
28067693	1175	1183	patients	T101	C0030705
28067693	1199	1227	Patient-controlled analgesia	T061	C0078944
28067693	1231	1239	morphine	T109,T121	C0026549
28067693	1240	1251	consumption	T169	C1512806
28067693	1266	1281	postoperatively	T079	C0032790
28067693	1286	1299	significantly	T078	C0750502
28067693	1300	1307	reduced	T080	C0392756
28067693	1315	1323	ketamine	T109,T121	C0022614
28067693	1348	1355	placebo	T122	C1696465
28067693	1390	1394	mean	T081	C0444504
28067693	1395	1405	difference	T080	C1705242
28067693	1417	1436	confidence interval	T081	C0009667
28067693	1461	1469	Sedation	T033	C0235195
28067693	1474	1487	significantly	T078	C0750502
28067693	1488	1495	reduced	T080	C0392756
28067693	1503	1511	ketamine	T109,T121	C0022614
28067693	1533	1548	postoperatively	T079	C0032790
28067693	1561	1587	no significant differences	T033	C3842396
28067693	1598	1608	acute pain	T184	C0184567
28067693	1610	1616	nausea	T184	C0027497
28067693	1618	1626	vomiting	T184	C0042963
28067693	1628	1642	hallucinations	T048	C0018524
28067693	1647	1657	nightmares	T184	C0028084
28067693	1659	1668	Back pain	T184	C0004604
28067693	1681	1696	postoperatively	T079	C0032790
28067693	1711	1723	preoperative	T079	C0445204
28067693	1724	1728	pain	T184	C0030193
28067693	1733	1746	significantly	T078	C0750502
28067693	1752	1760	improved	T033	C0184511
28067693	1768	1776	ketamine	T109,T121	C0022614
28067693	1801	1808	placebo	T122	C1696465
28067693	1842	1856	intraoperative	T079	C0456904
28067693	1857	1865	ketamine	T109,T121	C0022614
28067693	1866	1879	significantly	T078	C0750502
28067693	1880	1887	reduced	T080	C0392756
28067693	1888	1896	morphine	T109,T121	C0026549
28067693	1897	1908	consumption	T169	C1512806
28067693	1909	1922	0 to 24 hours	T079	C0439585
28067693	1929	1950	lumbar fusion surgery	T061	C0186045
28067693	1954	1960	opioid	T109,T121	C0002772
28067693	1963	1972	dependent	T080	C0851827
28067693	1973	1981	patients	T101	C0030705
28067693	1987	1992	trend	T079	C1521798
28067693	2008	2018	persistent	T079	C0205322
28067693	2019	2023	pain	T184	C0030193
28067693	2033	2048	postoperatively	T079	C0032790
28067693	2055	2062	further	T082	C1517331
28067693	2063	2076	investigation	T169	C1292732